Advanced in Peripheral T-Cell Lymphoma

Oussama A. Abla

555 University Avenue, 
Toronto, ON, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Advanced in Peripheral T-Cell Lymphoma
555 University Avenue, 
Toronto, ON, CA 
OverviewLocationsClinical Research

Overview

Oussama Abla practices in Toronto, Canada. Mr. Abla is rated as an Advanced expert by MediFind in the treatment of Peripheral T-Cell Lymphoma. His top areas of expertise are Langerhans Cell Histiocytosis, Reticulohistiocytoma, Histiocytosis, and Rosai-Dorfman Disease.

His clinical research consists of co-authoring 87 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Peripheral T-Cell Lymphoma.

Gender
Male

Locations

555 University Avenue, Toronto, ON, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
Enrollment Status: Recruiting
Publish Date: May 25, 2025
Intervention Type: Drug, Procedure, Biological
Study Drugs: Prednisone, Vinblastine, Mercaptopurine, Indomethacin, Methotrexate, Cytosine Arabinoside, 2-chlorodeoxyadenosine, Intravenous immunoglobulin
Study Phase: Phase 2/Phase 3
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Enrollment Status: Active_not_recruiting
Publish Date: October 07, 2025
Intervention Type: Drug, Radiation
Study Drugs: Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin, Doxorubicin, Etoposide, Hydrocortisone Sodium Succinate, Ifosfamide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Thioguanine, Vincristine, Vincristine Sulfate
Study Phase: Phase 3
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)
Enrollment Status: Active_not_recruiting
Publish Date: August 12, 2025
Intervention Type: Other, Procedure, Drug
Study Drug: Tyrosine Kinase Inhibitor
Study Phase: Phase 2
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2024
Intervention Type: Other, Drug
Study Drugs: Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Mitoxantrone, Tretinoin
Study Phase: Phase 3
View 3 Less Clinical Trials

87 Total Publications

Value of 18F-FDG PET/CT Scans in Staging and Follow-Up of Pediatric Langerhans Cell Histiocytosis: Comparison to CT and/or MRI.
Value of 18F-FDG PET/CT Scans in Staging and Follow-Up of Pediatric Langerhans Cell Histiocytosis: Comparison to CT and/or MRI.
Journal: Children (Basel, Switzerland)
Published: July 04, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Abla's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 17 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile